Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Niraparib

SKU: orb1304399

Description

Niraparib (MK-4827) is a potent and selective PARP1/2 inhibitor (IC50=3.8/2.1 nM) that impedes DNA repair, leading to apoptosis. It is widely used in oncology research, demonstrating antitumor efficacy in both cellular assays and in vivo models of BRCA-mutated and homologous recombination-deficient cancers.

Research Area

Pharmacology & Drug Discovery

Images & Validation

−
Niraparib

Key Properties

−
CAS Number1038915-60-4
MW320.39
Purity99.91% (May vary between batches)
FormulaC19H20N4O
SMILESC(N)(=O)C=1C=2C(=CN(N2)C3=CC=C(C=C3)[C@@H]4CCCNC4)C=CC1
TargetPARP,Apoptosis
SolubilityDMSO:65.63 mg/mL (204.84 mM);Ethanol:60 mg/mL (187.27 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:6 mg/mL (18.73 mM)

Bioactivity

−
Target IC50
PARP4:330 nM|tankyrase 1:570 nM|PARP2:2.1 nM|PARP1:3.8 nM|PARP3:1300 nM
In Vivo
METHODS: To detect anti-tumor activity in vivo, Niraparib (25 mg/kg, administered orally four times per week) and PD-L1 (10 mg/kg, administered intraperitoneally twice per week) were administered to C57BL/6 mice bearing ovarian cancer tumor ID8 for eight weeks. RESULTS: Niraparib upregulated PD-L1 expression in ovarian tumors in vivo and synergized with PD-L1 blockade. METHODS: To detect anti-tumor activity in vivo, Niraparib (50 mg/kg, 0.5% methylcellulose) was administered by gavage to C57BL/6 mice bearing intracranial human-derived TNBC cell lines SUM149, MDA-MB-231Br, or MDA-MB-436 once daily for two weeks. RESULTS: In the BRCA mutant MDA-MB-436 model, Niraparib increased median survival and decreased tumor load. However, it did not increase in the BRCA mutant SUM149 or BRCA wild-type MDA-MB-231Br models, despite high concentrations in intracranial tumors.
Read more...
In Vitro
METHODS: The PDAC cell lines MIA-PaCa-2, PANC-1, Capan-1 and the OvCa cell lines OVCAR8, PEO1 were treated with Niraparib (0.1-200 µM) for 48 h, and the cells were assayed for viability using the CellTiter-Glo Luminescent Cell Viability Assay. RESULTS: The IC50 of Niraparib on MIA-PaCa-2, PANC-1, Capan-1, OVCAR8, and PEO1 cells were 26 µm, 50 µm, 15 µM, 20 µM, and 28 µM, respectively. . METHODS: Ovarian cancer cells SKOV3 and UWB1.289 were treated with Niraparib (0.5-15 µM) for 48 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Niraparib upregulated the expression of PD-L1 in SKOV3 and UWB1.289 cells.
Read more...
Cell Research
Proliferation assays were conducted in 96-well black viewplates, and 300 cells/well (250 cell/well for BRCA-1 wt) in culture medium, 190 μL/well (DMEM containing 10% FCS, 0.1 mg/mL penicillin-streptomycin, and 2 mM L-glutamine), were plated and incubated for 4 h at 37℃ under 5% CO2 atmosphere. Inhibitors were then added with serial dilutions, 10 μL/well to obtain the desired final compound concentration in 0.5% DMSO. The cells were then incubated for 7 days at 37℃ in 5% CO2 after which time viability was assessed. Briefly, with CellTiter-Blue solution prediluted 1:10 in medium, 100 μL/well was added and the cells left for 45 min at 37℃ under 5% CO2 and then a further 15 min at room temperature in the dark. The number of living cells was determined by reading the plate at fluorimeter, excitation at 550 nm and emission at 590 nm. Cell growth was expressed as the percentage growth with respect to vehicle treated cells. The concentration required to inhibit cell growth by 50% (CC50) was determined.(Only for Reference)
Read more...

Storage & Handling

−
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
breast, damage, DNA, bioavailable, cancer, Apoptosis, anti-tumor, Inhibitor, MK-4827, MK4827, MK 4827, PARP2, PARP3, PARP1, PARP, ovarian, poly ADP ribose polymerase, Niraparib, orally, inhibit, lung, TANK-1, V-PARP

Similar Products

−
  • MK-4827 Racemate

    MK-4827 Racemate [orb1305758]

    99.86% (May vary between batches)

    1038915-75-1

    320.39

    C19H20N4O

    2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 mg, 1 ml x 10 mM (in DMSO)
  • Niraparib (R-enantiomer)

    Niraparib (R-enantiomer) [orb1309416]

    99.83% (May vary between batches)

    1038915-58-0

    320.39

    C19H20N4O

    5 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO), 1 mg, 10 mg
  • Niraparib tosylate

    Niraparib tosylate [orb1300371]

    99.87% (May vary between batches)

    1038915-73-9

    492.59

    C19H20N4O·C7H8O3S

    1 ml x 10 mM (in DMSO), 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
  • Niraparib tosylate monohyrate

    Niraparib tosylate monohyrate [orb1298065]

    99.99% (May vary between batches)

    1613220-15-7

    510.61

    C26H30N4O5S

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 ml x 10 mM (in DMSO)
  • Niraparib metabolite M1

    Niraparib metabolite M1 [orb1709021]

    99.65% (May vary between batches)

    1476777-06-6

    321.37

    C19H19N3O2

    25 mg, 5 mg, 10 mg, 1 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID
24958200 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

Niraparib (orb1304399)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
¥ 1,300.00
1 ml x 10 mM (in DMSO)
¥ 1,430.00
10 mg
¥ 1,560.00
25 mg
¥ 2,080.00
50 mg
¥ 2,470.00
100 mg
¥ 3,510.00
200 mg
¥ 4,940.00
500 mg
¥ 8,060.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

[email protected]

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor